Incidence of pertussis in subjects aged 50years and older in France in 2013-2014.
N Guiso, J-L Gallais, G Gavazzi...
https://pubmed.ncbi.nlm.nih.gov/29037454Actively Recruiting
Age: 18Years - 99Years
All Genders
ID06286007
Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control
Led by Hospital Clinico Universitario de Santiago · Updated on 2024-03-01
784
Participants Needed
1
Research Sites
100 weeks
Total Duration
On this page
Sponsors
H
Hospital Clinico Universitario de Santiago
Lead Sponsor
T
Translational Research In Airway Diseases Group (TRIAD)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Researchers are studying the yearly frequency of Bordetella pertussis and respiratory syncytial virus (RSV) infections in adults aged 18 and older who have asthma. The study is a multicenter prospective cohort conducted across 35 centers in Spain. It aims to identify these infections using PCR tests performed at specific times after symptoms begin in patients with acute respiratory infections (ARI). Participants will report any asthma flare-ups or acute respiratory infection symptoms over a two-year follow-up. When symptoms occur, a nasopharyngeal swab PCR test will be done for pertussis if symptoms started within the past three weeks, and for RSV if symptoms began within the past 72 hours. This helps to detect and track the infections during the study period. During the study, participants will regularly report symptoms, and researchers will collect samples based on symptom timing. They will measure the incidence of pertussis and RSV infections over two years and assess asthma severity and control linked to these infections. The study also includes seroprevalence evaluations for both pathogens. Participants’ data and health status will be monitored throughout the follow-up period.
CONDITIONS
Brief Title
Prevalence and Impact of Pertussis and RSV on Asthma Severity and Control
Who Can Participate
Age: 18Years - 99Years
All Genders
Eligibility Criteria
You may qualify if you...
- Adult patient aged 18 years and over
- Diagnosed with asthma at least one year before enrollment
- Able and willing to comply with study requirements during follow-up
- Able to provide written informed consent
You will not qualify if you...
- History of pertussis infection within the last 12 months
- Acute respiratory infection within 2 weeks before enrollment
- Presence of respiratory diseases other than asthma
- Alcohol or drug abuse at enrollment
- Active cancer or under cancer treatment or follow-up
- Pregnant women
- Use of immunosuppressive or immunomodulating agents unrelated to asthma
- Vaccinated for RSV prior to or during the study (data collected before vaccination included)
- Vaccinated for Bordetella pertussis within the past 12 months
- Plans to move away during the study period
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
1
2
3
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Diagnostic Evaluation
Duration - As needed during 2 years
Participants report symptoms of acute respiratory infection or asthma exacerbation and may undergo nasopharyngeal swab specimens for PCR testing for Bordetella pertussis and RSV based on symptom onset timing.
Visits occur depending on symptom onset within the 2-year follow-up
Long-term Monitoring
Duration - 2 years
Participants are followed for 2 years to monitor the incidence and impact of Bordetella pertussis and RSV infections on asthma severity and control.
Participants report symptoms as they occur; no scheduled visits
Trial Site Locations
Total: 1 location
1
Hospital Clínico Universitario de Santiago de Compostela
Santiago de Compostela, A Coruña, Spain, 15706
Actively Recruiting
Loading map...
Research Team
F
Francisco-Javier GONZALEZ BARCALA, MD, PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Published Research Related To This Trial
Long-lasting cough in an adult German population: incidence, symptoms, and related pathogens.
Raphael Weinberger, Marion Riffelmann, Nicole Kennerknecht...
https://pubmed.ncbi.nlm.nih.gov/29302815High healthcare resource utilisation due to pertussis in Australian adults aged 65 years and over.
Robert Neil F Leong, James G Wood, Bette Liu...
https://pubmed.ncbi.nlm.nih.gov/32220516Severe Pertussis Infections in the United States, 2011-2015.
Sarah A Mbayei, Amanda Faulkner, Christine Miner...
https://pubmed.ncbi.nlm.nih.gov/30321305Pertussis in high-risk groups: an overview of the past quarter-century.
Victoria A Jenkins, Miloje Savic, Walid Kandeil
https://pubmed.ncbi.nlm.nih.gov/32298213Controlling pertussis: how can we do it? A focus on immunization.
Federico Martinón-Torres, Ulrich Heininger, Angus Thomson...
https://pubmed.ncbi.nlm.nih.gov/29482390Burden of Pertussis in COPD: A Retrospective Database Study in England.
Emmanuel Aris, Lauriane Harrington, Amit Bhavsar...
https://pubmed.ncbi.nlm.nih.gov/33866914A systematic review of adult tetanus-diphtheria-acellular (Tdap) coverage among healthcare workers.
Bruno A Randi, Odeli Nicole Encinas Sejas, Karina T Miyaji...
https://pubmed.ncbi.nlm.nih.gov/30630694The pertussis hypothesis: Bordetella pertussis colonization in the etiology of asthma and diseases of allergic sensitization.
Keith Rubin, Steven Glazer
https://pubmed.ncbi.nlm.nih.gov/30220328Pertussis diagnosis in Belgium: results of the National Reference Centre for Bordetella anno 2015.
H Martini, C Rodeghiero, C VAN DEN Poel...
https://pubmed.ncbi.nlm.nih.gov/28578723